Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | FABP1 | P07148 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311473 | 0.88 | P2RX3 (0.62) | P2RX3P2RX2HPGDKMT2AMEN1 | |
| SCHEMBL27672236 | 0.82 | HPGD (0.66) | P2RX3P2RX2HPGDKMT2AMEN1 | |
| SCHEMBL311122 | 0.78 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL16456324 | 0.77 | HPGD (0.74) | P2RX3P2RX2HPGDKMT2AMEN1 | |
| SCHEMBL311016 | 0.76 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL27850662 | 0.72 | HPGD (0.48) | P2RX3P2RX2HPGDDHODHKMT2A | |
| SCHEMBL2174227 | 0.72 | ALDH1A1 (0.57) | HPGDDHODHKMT2AMEN1GAA | |
| SCHEMBL26280806 | 0.71 | MEN1 (0.44) | P2RX3P2RX2HPGDKMT2AMEN1 | |
| SCHEMBL16110125 | 0.71 | HPGD (0.49) | P2RX3P2RX2HPGDKMT2AMEN1 | |
| SCHEMBL31422646 | 0.70 | HPGD (1.00) | HPGDKMT2AMEN1GAATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | claimed |
| US-8809402-B2 | Oxazolone and pyrrolidinone-substituted biphenyls as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-08-19 | — | — | US | claimed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | claimed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2445889-B1 | NOVEL BENZOXAZOLONE -SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885HPGD 1562/4885 |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885HPGD 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.